These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9780970)

  • 1. Prostate cancer: 2. Natural history.
    Nam RK; Jewett MA; Krahn MD
    CMAJ; 1998 Sep; 159(6):685-91. PubMed ID: 9780970
    [No Abstract]   [Full Text] [Related]  

  • 2. The management of localized prostate cancer.
    Clarke NW
    Br J Hosp Med; 1996 Mar 6-19; 55(5):232-3. PubMed ID: 8777510
    [No Abstract]   [Full Text] [Related]  

  • 3. Natural history and staging of prostate cancer.
    Whitmore WF
    Urol Clin North Am; 1984 May; 11(2):205-20. PubMed ID: 6375067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenocarcinoma of the prostate.
    Von Eschenbach AC; Johnson DE
    Compr Ther; 1978 Aug; 4(8):18-26. PubMed ID: 688739
    [No Abstract]   [Full Text] [Related]  

  • 5. More about prostate cancer--expectant management versus treatment.
    Anscher MS
    N C Med J; 1999; 60(6):313-4. PubMed ID: 10581934
    [No Abstract]   [Full Text] [Related]  

  • 6. [Prostatic carcinoma: histoprognosis, prognostic value of Gleason's index].
    Saint-André JP; Rousselet MC; Six P; Bertrand G; Soret JY
    Bull Cancer; 1985; 72(5):414-22. PubMed ID: 4074910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenocarcinoma of the prostate: an overview.
    Droller MJ
    Urol Clin North Am; 1980 Oct; 7(3):579-81. PubMed ID: 7456170
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4.
    Lau WK; Blute ML; Bostwick DG; Weaver AL; Sebo TJ; Zincke H
    J Urol; 2001 Nov; 166(5):1692-7. PubMed ID: 11586204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostatic adenocarcinoma: pathological stage C. I: Diagnosis, technical aspects and significance].
    Flam T; Zerbib M; Steg A; Debré B
    J Urol (Paris); 1991; 97(1):5-9. PubMed ID: 1707935
    [No Abstract]   [Full Text] [Related]  

  • 11. Best practice statement on cryosurgery for the treatment of localized prostate cancer.
    Babaian RJ; Donnelly B; Bahn D; Baust JG; Dineen M; Ellis D; Katz A; Pisters L; Rukstalis D; Shinohara K; Thrasher JB
    J Urol; 2008 Nov; 180(5):1993-2004. PubMed ID: 18817934
    [No Abstract]   [Full Text] [Related]  

  • 12. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.
    Anscher MS; Clough R; Robertson CN; Prosnitz LR; Dahm P; Walther P; Donatucci CF; Albala DM; Febbo P; George DJ; Sun L; Moul JW
    Prostate Cancer Prostatic Dis; 2006; 9(3):254-60. PubMed ID: 16880828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome for lymph node-positive prostate cancer.
    Swanson GP; Riggs MW; Herman M
    Prostate Cancer Prostatic Dis; 2008; 11(2):198-202. PubMed ID: 17519924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural history of prostatic cancer.
    Hanash KA
    Prog Clin Biol Res; 1987; 243B():289-320. PubMed ID: 3659027
    [No Abstract]   [Full Text] [Related]  

  • 16. Difficult diagnostic and therapeutic cases: CASE 3. presentation of prostate cancer with cervical adenopathy.
    Gaur S; Aish LS; Oo TH
    J Clin Oncol; 2004 Mar; 22(5):957-8. PubMed ID: 14990654
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prognosis of prostate cancer with elevated prostatic acid phosphatase].
    Saito T; Kitamura Y; Komatsubara S
    Hinyokika Kiyo; 2006 Mar; 52(3):177-80. PubMed ID: 16617869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.
    Gleason DF; Mellinger GT;
    J Urol; 2017 Feb; 197(2S):S134-S139. PubMed ID: 28012760
    [No Abstract]   [Full Text] [Related]  

  • 20. Adenocarcinoma of the prostate.
    Swanson JO
    J Insur Med; 1997; 29(3):195-203. PubMed ID: 10176369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.